福泰制药(Vertex Pharmaceuticals)表示,根据当前已知的关税税率与相关法规,其2026年业绩指引中继续纳入的关税成本影响,仍属微不足道。
福泰制药(Vertex Pharmaceuticals)表示,根据当前已知的关税税率与相关法规,其2026年业绩指引中继续纳入的关税成本影响,仍属微不足道。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.